Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Precision Biosciences Inc

NASDAQ: DTIL · Life Sciences · 6 alerts · CIK 1357874

Share price
$7.28Close, Nov 16
Market cap
$203M
Shares outstanding
27.94MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Precision Biosciences Inc filings on SEC EDGAR ↗

8:11 AM ET 8-K
Financial Results

Precision Biosciences Financial Results

Precision BioSciences reported Q3 2026 financial results, highlighting a cash position of $108 million which is expected to fund operations through 2028. The company advanced its clinical pipeline, including dosing the first patient in the Phase 1/2 FUNCTION-DMD study and preparing for a late-breaking oral presentation of PBGENE-HBV data at AASLD's The Liver Meeting.

“We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress executing against that plan. In the third quarter, we continued to advance PBGENE-HBV in the ELIMINATE-B trial for chronic hepatitis B and are very excited about the opportunity to present important clinical data in a late-breaking oral presentation at the upcoming AASLD Liver Meeting on November 8th at 2:15pm MST.”

Michael Amoroso, Chief Executive Officer of Precision BioSciences

“The third quarter also marked an important milestone for Precision BioSciences and more importantly for the children who live with Duchenne muscular dystrophy (DMD). Our team alongside our investigators commenced dosing of the first patient in the FUNCTION-DMD trial.”

Michael Amoroso, Chief Executive Officer of Precision BioSciences
8:10 AM ET 10-Q
Financial Results

Precision Biosciences Q3 2026 Results: Net Loss of $7.59M, Loss Narrows

Precision BioSciences is a clinical-stage gene editing company focused on its ARCUS technology. As of October 29, 2026, the company had 27,935,719 shares of common stock outstanding and continues to report significant operating losses with a need for substantial additional funding to support its research and development programs.

Key figure
Net loss $7.59M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.